TPS reflects PD‐L1 expression only on tumor cells, while TMB serves as an indirect proxy for tumor antigenicity.[13, 65, 66] In contrast, LIRA was developed using 50 model genes derived from transcriptomic data through rigorous feature selection. This evidence concerns the gene CD274 and neoplasm.